NCT07615413尚未招募1 期
A Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of HS-10541 as Monotherapy or in Combination With Other Anti-cancer Therapies in Participants With KRAS G12C Mutation Advanced Solid Tumors.
Jiangsu Hansoh Pharmaceutical Co., Ltd.0 个研究点目标入组 636 人开始时间: 2026年6月30日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 636
研究概览
简要总结
This is a multicenter, open-label phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of HS-10541 as monotherapy or in combination with other anti-cancer therapies in participants with KRAS G12C mutation advanced solid tumors.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Voluntary participation and written informed consent..
- •Aged 18 years or older (≥18 years), of any gender.
- •Histologically or cytologically confirmed advanced solid tumor.
- •At least one measurable lesion according to RECIST v1.
- •ECOG PS of 0 to 1, with no deterioration within 2 weeks prior to the first dose.
- •With a life expectancy > 12 weeks.
- •Adequate bone marrow reserve and organ function.
- •Female participants of childbearing potential and non-sterilized male participants must agree to use highly effective contraceptive measures from the time of signing the ICF until 6 months after the last dose.
- •Female participants of childbearing potential must be non-lactating; all female participants must have a negative pregnancy test prior to the first dose.
排除标准
- •Uncontrolled pleural effusion, pericardial effusion, or abdominal effusion requiring clinical intervention.
- •Presence of symptomatic brain metastases, leptomeningeal/brainstem involvement, history of intracranial hemorrhage or intraspinal hemorrhage, or spinal cord compression.
- •Unresolved CTCAE ≥grade 2 toxicities from previous anticancer therapy.
- •History of a second primary malignancy
- •Severe, uncontrolled, or active cardiovascular or cerebrovascular diseases, or severe cardiac examination abnormalities.
- •Severe or poorly controlled diabetes mellitus or hypertension.
- •Known active infectious diseases.
- •Clinically significant gastrointestinal dysfunction.
- •Gastrointestinal obstruction or perforation occured.
- •Interstitial lung disease (ILD).
- •Participants with known hypersensitivity or contraindications to any active or inactive ingredients of the study drug, chemically similar drugs, or drugs of the same class.
- •Other inappropriate situation considered by the investigator.
研究者
相似试验
招募中
1 期
A Study of MG2512 Injection in Participants With Advanced Solid TumorsNCT07348653Shanghai Mabgen Biopharmaceutical Technology Co., Ltd.116
尚未招募
1 期
Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HLX97 (a KAT6A/B Inhibitor) in Patients With Advanced/Metastatic Solid TumorNCT07480681Shanghai Henlius Biotech138
尚未招募
1 期
A Study of DXC006 With Immune Checkpoint Inhibitors or Platinum for Small Cell Lung Cancer.Small Cell Lung CancerNCT07559929Hangzhou DAC Biotechnology Co., Ltd.200
尚未招募
1 期
A Clinical Study of ZL-85FA TabletsNCT07339748Chengdu Zenitar Biomedical Technology Co., Ltd51
暂停
2 期
ARN-75039 Lassa Fever Treatment in West AfricaLassa FeverNCT07419373Arisan Therapeutics, Inc.135